Tempest Therapeutics, Inc. (TPST)
0.873
-0.04
(-3.95%)
USD |
NASDAQ |
Sep 10, 12:06
Tempest Therapeutics EPS Diluted (Quarterly) : -0.3445 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3445 |
| March 31, 2026 | -2.534 |
| December 31, 2025 | -0.8161 |
| September 30, 2025 | -0.7907 |
| June 30, 2025 | -2.069 |
| March 31, 2025 | -3.159 |
| December 31, 2024 | -4.084 |
| September 30, 2024 | -0.409 |
| June 30, 2024 | -0.4245 |
| March 31, 2024 | -0.3555 |
| December 31, 2023 | -0.3479 |
| September 30, 2023 | -0.4805 |
| June 30, 2023 | -0.5376 |
| March 31, 2023 | -0.5548 |
| December 31, 2022 | -0.8654 |
| September 30, 2022 | -0.6561 |
| June 30, 2022 | -0.7922 |
| March 31, 2022 | -1.185 |
| December 31, 2021 | -1.126 |
| September 30, 2021 | -1.207 |
| June 30, 2021 | -7.627 |
| March 31, 2021 | -158.29 |
| December 31, 2020 | -1597.68 |
| September 30, 2020 | -11.22 |
| June 30, 2020 | -11.42 |
| Date | Value |
|---|---|
| March 31, 2020 | -9.755 |
| December 31, 2019 | -13.06 |
| September 30, 2019 | -13.00 |
| June 30, 2019 | -11.07 |
| March 31, 2019 | -11.64 |
| September 30, 2018 | -2386.86 |
| June 30, 2018 | -1534.86 |
| March 31, 2018 | -17544.49 |
| December 31, 2017 | -702.00 |
| September 30, 2017 | -58.50 |
| June 30, 2017 | -1491.75 |
| March 31, 2017 | -94.50 |
| December 31, 2016 | -144.00 |
| September 30, 2016 | -121.50 |
| June 30, 2016 | -139.50 |
| March 31, 2016 | -180.00 |
| December 31, 2015 | -171.00 |
| September 30, 2015 | -148.50 |
| June 30, 2015 | -144.00 |
| March 31, 2015 | -146.25 |
| December 31, 2014 | -177.75 |
| September 30, 2014 | -121.50 |
| June 30, 2014 | -94.50 |
| March 31, 2014 | -92.25 |
| December 31, 2013 | -144.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.244M |
| Total Expenses (Quarterly) | 5.244M |
| Enterprise Value | 21.30M |
| Earnings Yield | -513.7% |
| Normalized Earnings Yield | -351.04 |